方盛制药通过药品GMP符合性检查

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating progress in regulatory compliance for its production facilities [1] Group 1: Inspection Details - The inspection covers the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - Specific areas inspected include Zone B and Zone E for Ezetimibe, and Zone A and Zone E for Benidipine in the raw material drug workshop [1]